Retension Pharmaceuticals
MCLEAN, VA · Biotechnology, Healthcare, Health Care · 10 employees
Retension Pharmaceuticals is developing RTN-001, a differentiated, tissue-targeted PDE5 inhibitor that has been optimized for the treatment of uncontrolled hypertension. RTN-001 has been evaluated in over 265 subjects across 9 clinical trials. In these studies, RTN-001 was well tolerated and demonstrated a sustained and clinically significant impact on central and brachial blood pressure in patien
Funding history
- Series B — $15.0M — Aug 2025
- Venture - Series Unknown — $12.3M — May 2025
- Series A — $10.4M — Aug 2024
Recent signals
- May 27, 2026: Retension Pharmaceuticals Appoints Alison Schecter as Chief Medical Officer and Alex Schwartz as Chief Financial Officer
- Aug 06, 2025: Raised $15.0M in Series B
- May 06, 2025: Raised $12.3M in Venture - Series Unknown
- Aug 21, 2024: Raised $10.4M in Series A
See plans & pricing → Track Retension Pharmaceuticals’s funding, hiring, and signals — with verified contacts — on Fundz.